• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

高龄(≥80 岁)患者行导管消融治疗心房颤动的安全性和有效性:来自加州大学圣地亚哥房颤消融登记研究的结果。

Safety and efficacy of catheter ablation of atrial fibrillation in the very elderly (≥80 years old): Insights from the UC San Diego AF Ablation Registry.

机构信息

Division of Cardiac Electrophysiology at the University of California San Diego Health System, La Jolla, California, USA.

A. T. Still University School of Osteopathic Medicine, Mesa, Arizona, USA.

出版信息

Clin Cardiol. 2023 Dec;46(12):1488-1494. doi: 10.1002/clc.24137. Epub 2023 Aug 25.

DOI:10.1002/clc.24137
PMID:37626475
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10716336/
Abstract

BACKGROUND

Catheter ablation improves outcomes in symptomatic atrial fibrillation (AF) patients. However, its safety and efficacy in the very elderly (≥80 years old) is not well described.

HYPOTHESIS

Ablation of AF in the very elderly is safe and effective.

METHODS

We performed a retrospective study of all patients who underwent catheter ablation enrolled in the University of California, San Diego AF Ablation Registry. The primary outcome was freedom from atrial arrhythmias on or off antiarrhythmic drugs (AADs).

RESULTS

Of 847 patients, 42 (5.0%) were 80 years of age or greater with a median age of 81.5 (80-82.3) and 805 (95.0%) were less than 80 years of age with a median age of 64.4 (57.6-70.2). Among those who were ≥80 years old, 29 were undergoing de novo ablation (69.0%), whereas in the younger cohort, 518 (64.5%) were undergoing de novo ablation (p = .548). There were no statistically significant differences in fluoroscopy (p = .406) or total procedure times (p = .076), AAD use (p = .611), or procedural complications (p = .500) between groups. After multivariable adjustment, there were no statistically significant differences in recurrence of any atrial arrhythmias on or off AAD (adjusted hazard ratio [AHR]: 0.75; 95% confidence interval [CI]: 0.45-1.23; p = .252), all-cause hospitalizations (AHR: 0.86; 95% CI: 0.46-1.60; p = .626), or all-cause mortality (AHR: 4.48; 95% CI: 0.59-34.07; p = .147) between the very elderly and the younger cohort.

CONCLUSION

In this registry analysis, catheter ablation of AF appears similarly effective and safe in patients 80 years or older when compared to a younger cohort.

摘要

背景

导管消融可改善有症状的心房颤动(AF)患者的预后。然而,其在非常高龄(≥80 岁)患者中的安全性和疗效尚不清楚。

假设

高龄患者的 AF 消融是安全有效的。

方法

我们对所有在加利福尼亚大学圣地亚哥房颤消融登记处接受导管消融的患者进行了回顾性研究。主要结局是停用或不停用抗心律失常药物(AAD)时无房性心律失常。

结果

847 例患者中,42 例(5.0%)年龄≥80 岁,中位年龄 81.5(80-82.3)岁,805 例(95.0%)年龄<80 岁,中位年龄 64.4(57.6-70.2)岁。≥80 岁的患者中,29 例为初次消融(69.0%),而在年龄较小的患者中,518 例(64.5%)为初次消融(p=0.548)。两组间透视时间(p=0.406)或总手术时间(p=0.076)、AAD 使用(p=0.611)或手术并发症(p=0.500)无统计学差异。多变量调整后,两组间任何 AAD 或不停用 AAD 时房性心律失常的复发率(调整后的危险比 [AHR]:0.75;95%置信区间 [CI]:0.45-1.23;p=0.252)、全因住院率(AHR:0.86;95%CI:0.46-1.60;p=0.626)或全因死亡率(AHR:4.48;95%CI:0.59-34.07;p=0.147)无统计学差异。

结论

在这项登记分析中,与年轻队列相比,80 岁或以上患者的 AF 导管消融在疗效和安全性方面似乎相似。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9fd/10716336/57d0b8f1cd82/CLC-46-1488-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9fd/10716336/b03622219bde/CLC-46-1488-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9fd/10716336/57d0b8f1cd82/CLC-46-1488-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9fd/10716336/b03622219bde/CLC-46-1488-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9fd/10716336/57d0b8f1cd82/CLC-46-1488-g003.jpg

相似文献

1
Safety and efficacy of catheter ablation of atrial fibrillation in the very elderly (≥80 years old): Insights from the UC San Diego AF Ablation Registry.高龄(≥80 岁)患者行导管消融治疗心房颤动的安全性和有效性:来自加州大学圣地亚哥房颤消融登记研究的结果。
Clin Cardiol. 2023 Dec;46(12):1488-1494. doi: 10.1002/clc.24137. Epub 2023 Aug 25.
2
Association of isoproterenol infusion during catheter ablation of atrial fibrillation with outcomes: insights from the UC San Diego AF Ablation Registry.异丙肾上腺素输注在心房颤动导管消融中的作用:来自加州大学圣地亚哥房颤消融登记处的研究结果。
J Interv Card Electrophysiol. 2023 Aug;66(5):1243-1252. doi: 10.1007/s10840-022-01448-x. Epub 2022 Dec 12.
3
Comparison of Outcomes After Ablation of Atrial Fibrillation in Patients With Heart Failure With Preserved Versus Reduced Ejection Fraction.心力衰竭射血分数保留与降低患者心房颤动消融术后结局比较。
Am J Cardiol. 2020 Dec 1;136:62-70. doi: 10.1016/j.amjcard.2020.09.018. Epub 2020 Sep 15.
4
Effect of Catheter Ablation Using Pulmonary Vein Isolation With vs Without Posterior Left Atrial Wall Isolation on Atrial Arrhythmia Recurrence in Patients With Persistent Atrial Fibrillation: The CAPLA Randomized Clinical Trial.导管消融术采用肺静脉隔离与不隔离左心房后壁对持续性心房颤动患者房性心律失常复发的影响:CAPLA 随机临床试验。
JAMA. 2023 Jan 10;329(2):127-135. doi: 10.1001/jama.2022.23722.
5
Very long-term outcomes after a single catheter ablation procedure for the treatment of atrial fibrillation-the protective role of antiarrhythmic drug therapy.单次导管消融术治疗心房颤动后的长期预后——抗心律失常药物治疗的保护作用
J Interv Card Electrophysiol. 2018 Jun;52(1):39-45. doi: 10.1007/s10840-018-0340-4. Epub 2018 Mar 6.
6
Efficacy and safety of high-power short duration atrial fibrillation ablation in elderly patients.高能短时间心房颤动消融术治疗老年患者的疗效和安全性。
J Cardiovasc Electrophysiol. 2022 Jul;33(7):1425-1434. doi: 10.1111/jce.15504. Epub 2022 May 6.
7
Pulsed Field Ablation as First-Line Therapy for Atrial Fibrillation: A Substudy of the EU-PORIA Registry.脉冲场消融作为心房颤动的一线治疗:欧盟PORIA注册研究的一项子研究
Circ Arrhythm Electrophysiol. 2024 Dec;17(12):e013088. doi: 10.1161/CIRCEP.124.013088. Epub 2024 Nov 27.
8
Curative catheter ablation in atrial fibrillation and typical atrial flutter: systematic review and economic evaluation.心房颤动和典型心房扑动的根治性导管消融术:系统评价与经济评估
Health Technol Assess. 2008 Nov;12(34):iii-iv, xi-xiii, 1-198. doi: 10.3310/hta12340.
9
Bayesian network meta-analysis comparing cryoablation, radiofrequency ablation, and antiarrhythmic drugs as initial therapies for atrial fibrillation.贝叶斯网络荟萃分析比较冷冻消融、射频消融和抗心律失常药物作为心房颤动的初始治疗方法。
J Cardiovasc Electrophysiol. 2022 Feb;33(2):197-208. doi: 10.1111/jce.15308. Epub 2021 Dec 11.
10
Five-year follow-up after catheter ablation of persistent atrial fibrillation using the stepwise approach and prognostic factors for success.采用逐步法消融持续性心房颤动 5 年后的随访及成功的预测因素。
Circ Arrhythm Electrophysiol. 2015 Apr;8(2):308-17. doi: 10.1161/CIRCEP.114.001672. Epub 2015 Mar 5.

引用本文的文献

1
Safety and Outcomes of Catheter Ablation for Consecutive Atrial Tachycardia in Elderly Patients After Previous Cardiac Interventions.既往心脏介入治疗后老年患者连续性房性心动过速导管消融的安全性及结局
J Clin Med. 2025 Jan 21;14(3):675. doi: 10.3390/jcm14030675.
2
Temporal trends of catheter ablation procedures in patients with atrial fibrillation and atrial flutter: A nationwide cohort study.心房颤动和心房扑动患者导管消融手术的时间趋势:一项全国性队列研究。
Int J Cardiol Heart Vasc. 2024 Oct 23;55:101541. doi: 10.1016/j.ijcha.2024.101541. eCollection 2024 Dec.
3
Disparities in the access to atrial fibrillation ablation in Denmark: who gets ablated, who neglected?

本文引用的文献

1
Do Elderly Patients with Atrial Fibrillation Have Comparable Ablation Outcomes Compared to Younger Ones? Evidence from Pooled Clinical Studies.老年房颤患者与年轻患者相比,消融结果是否相当?来自汇总临床研究的证据。
J Clin Med. 2022 Jul 31;11(15):4468. doi: 10.3390/jcm11154468.
2
Two-year outcomes of more than 30 000 elderly patients with atrial fibrillation: results from the All Nippon AF In the Elderly (ANAFIE) Registry.超过 30000 名老年房颤患者的两年结局:来自全日本老年房颤注册研究(ANAFIE)的结果。
Eur Heart J Qual Care Clin Outcomes. 2022 Mar 2;8(2):202-213. doi: 10.1093/ehjqcco/qcab025.
3
Early Rhythm-Control Therapy in Patients with Atrial Fibrillation.
丹麦心房颤动消融治疗的可及性差异:谁得到了消融治疗,谁被忽视了?
Europace. 2024 Aug 30;26(9). doi: 10.1093/europace/euae231.
4
Response to Letter to the Editor.对编辑来信的回复。
Clin Cardiol. 2024 Feb;47(2):e24202. doi: 10.1002/clc.24202. Epub 2023 Dec 19.
5
Efficacy and feasibility of catheter ablation in elderly patients with atrial fibrillation.导管消融治疗老年房颤患者的疗效及可行性
Clin Cardiol. 2024 Feb;47(2):e24195. doi: 10.1002/clc.24195. Epub 2023 Nov 16.
心房颤动患者的早期节律控制治疗。
N Engl J Med. 2020 Oct 1;383(14):1305-1316. doi: 10.1056/NEJMoa2019422. Epub 2020 Aug 29.
4
Safety of catheter ablation for atrial fibrillation in the octogenarian population.老年人群心房颤动导管消融的安全性。
J Cardiovasc Electrophysiol. 2019 Dec;30(12):2686-2693. doi: 10.1111/jce.14165. Epub 2019 Oct 13.
5
2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons.2019年美国心脏协会/美国心脏病学会/心律学会对2014年美国心脏协会/美国心脏病学会/心律学会心房颤动患者管理指南的聚焦更新:美国心脏病学会/美国心脏协会临床实践指南工作组和心律学会与胸外科医师协会合作报告
Circulation. 2019 Jul 9;140(2):e125-e151. doi: 10.1161/CIR.0000000000000665. Epub 2019 Jan 28.
6
Uninterrupted direct oral anticoagulants vs. uninterrupted vitamin K antagonists during catheter ablation of non-valvular atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials.非瓣膜性心房颤动导管消融中直接口服抗凝剂与维生素 K 拮抗剂不间断治疗的比较:随机对照试验的系统评价和荟萃分析。
Europace. 2018 Oct 1;20(10):1612-1620. doi: 10.1093/europace/euy133.
7
Heart Disease and Stroke Statistics-2018 Update: A Report From the American Heart Association.《2018年心脏病和中风统计数据更新:美国心脏协会报告》
Circulation. 2018 Mar 20;137(12):e67-e492. doi: 10.1161/CIR.0000000000000558. Epub 2018 Jan 31.
8
2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary.2017年心房颤动导管消融与外科消融治疗专家共识声明:执行摘要(由心律学会[HRS]、欧洲心律协会[EHRA]、欧洲心血管病预防与康复协会[ECAS]、亚太心律学会[APHRS]及拉丁美洲心律学会[SOLAECE]联合发布)
J Arrhythm. 2017 Oct;33(5):369-409. doi: 10.1016/j.joa.2017.08.001. Epub 2017 Sep 15.
9
Depression and frailty in later life: a systematic review.晚年的抑郁症与衰弱:一项系统综述
Clin Interv Aging. 2015 Dec 15;10:1947-58. doi: 10.2147/CIA.S69632. eCollection 2015.
10
Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) randomized trial.不同抗凝管理的房颤导管消融患者围术期卒中与出血并发症:来自华法林在房颤(AF)患者导管消融中预防血栓栓塞(COMPARE)随机试验的作用(Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation,COMPARE)的研究结果。
Circulation. 2014 Jun 24;129(25):2638-44. doi: 10.1161/CIRCULATIONAHA.113.006426. Epub 2014 Apr 17.